Literature DB >> 16877694

Inhaled corticosteroids and mortality in COPD.

P Ernst, S Suissa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16877694      PMCID： PMC2104680     

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  4 in total

1.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

2.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Authors:  E F M Wouters; D S Postma; B Fokkens; W C J Hop; J Prins; A F Kuipers; H R Pasma; C A J Hensing; E C Creutzberg
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

3.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.

Authors:  D D Sin; L Wu; J A Anderson; N R Anthonisen; A S Buist; P S Burge; P M Calverley; J E Connett; B Lindmark; R A Pauwels; D S Postma; J B Soriano; W Szafranski; J Vestbo
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

4.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; Paige Lacy; Ernest York; S F Paul Man
Journal:  Am J Respir Crit Care Med       Date:  2004-06-30       Impact factor: 21.405
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.